Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Educators Post Observer.
Anthem Pleasant Launches AnthemStamps.com, Becomes Philatelic Advisor After a Decade of Study
Anthem Pleasant launches AnthemStamps.com, offering investment-grade philatelic advisory and curated postage for weddings, holidays, and VIP invitations. SCOTTSDALE, AZ, UNITED STATES, October 14, 2025 /EINPresswire.com/ -- Entrepreneur and...
NIH-Funded Study: Brain Chemistry Breakthrough to Reverse Cognitive Aging
SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- A new peer-reviewed brain imaging study shows a novel intervention can significantly upregulate the production of a key brain chemical — acetylcholine (sometimes called the “pay attention”...
Courage Is A Habit Exposes American School Counselor Association's Direct Ties to Radical Southern Poverty Law Center
NOBLESVILLE, Ind., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Courage Is A Habit (CIAH), the premier advocacy group empowering parents to defend their children against ideological indoctrination in education, today announces a bombshell update to its...
Smackover Lithium Files Definitive Feasibility Study for Its South West Arkansas Project, North America’s Highest-Grade Reported Lithium Brine Reserve
LEWISVILLE, Ark., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a 55:45 owned Joint Venture (“JV”) between Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI) and Equinor (“Equinor”), announced today that...
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established plans to accelerate patient...
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced positive results from...
We must work together if we are to ensure that no person goes hungry
Dear Fellow South African, Last week, the 7th Social Justice Summit, organised by the Centre for Social Justice at Stellenbosch University, reflected on our country’s progress towards achieving food security as a key component of social justice....
Owner: South African Government
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the...
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this year NDA submission for bezuclastinib planned...
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
PRESS RELEASE AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH VERY UNFAVORABLE GENETIC...
Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from solid tumors, confirming proof-of-concept with Phase 2 topline results expected by H1 2026 First cohort of patients in...
Books of Discovery Empowers Students with Applied Anatomy and Physiology for Manual Therapists
Students gain essential knowledge with Applied Anatomy and Physiology for Manual Therapists, a key resource from Books of Discovery. BOULDER, CO, UNITED STATES, October 13, 2025 /EINPresswire.com/ -- Books of Discovery, a trusted name in...
Reimagining Education: How AI Can Teach Kids to Think Again
DENVER, Oct. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com - Students have access to more information than ever, yet literacy, attention, and imagination are all in decline. We’re not running a knowledge deficit, but more children are no longer...
Quantum Dot Materials and Technologies Market Size at USD 48.2 billion by 2035 | Samsung, Nanosys, Quantum Solution, TCL
Quantum dot materials and technologies market is projected to grow from USD 8.5 billion in 2025 to USD 48.2 billion by 2035, advancing at a CAGR of 18.9%. ROCKVILLE, MD, UNITED STATES, October 13, 2025 /EINPresswire.com/ -- The global Quantum...
National School Lunch Week challenges students to ‘Taste the World’
If you’re already thinking about lunch for today, you’re not alone. With nearly 58 million school lunches served to Iowa K-12 students through the National School Lunch Program each year, school nutrition programs are busy at work, preparing...
Owner: American Government
American Battery Technology Company Completes All Required NEPA Baseline Studies for its Tonopah Flats Lithium Project, One of the Largest Critical Mineral Lithium Projects in the U.S.
Reno, Nev., Oct. 13, 2025 (GLOBE NEWSWIRE) -- American Battery Technology Company (NASDAQ: ABAT), an integrated critical battery materials company commercializing both its primary battery mineral manufacturing and lithium-ion battery recycling...
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR ≤0.5 g/g) achieved in one-third of patients and sustained through one year Two...
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or...
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC) Positive delayed-type hypersensitivity (DTH) – a potential biomarker predictive of improved clinical...
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for...